Screener / SEC EDGAR /CIK 0000096943 /10-K filed Feb 27, 2026, compared with Feb 28, 2025 /Numbers from the XBRL of the 10-Ks
NYSE Health care · Medical Instruments

Teleflex Inc TFX

Compare with peers Embed
The 10-K against last year's

154 changes: 31 added, 34 removed, 84 reworded, 5 quiet changes

10-K Feb 27, 2026 vs Feb 28, 2025

10-K 0000096943-26-000019 (Feb 27, 2026) vs 10-K 0000096943-25-000031 (Feb 28, 2025)

Every paragraph, and how much of it changed

One bar per paragraph, in the order of the 10-K. Height and colour show the share of its words not in the closest paragraph a year earlier; the tallest bars are new paragraphs.

Risk Factors

131 paragraphs · 7 new · 26 reworded · 7 gone · 10-K Feb 27, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 57 · 37% changed Every version of it
We are subject to risks associated with public health threats, such as the recent COVID-19 epidemic and pandemic. As with COVID-19, such Such events could significantly impact economic activity and markets around the world and, as a result, have negative effects on our operations, financial performance and cash flows. Such effects would depend on various factors, including, but not limited, to: the occurrence, spread, duration and severity of any outbreaks; governmental, business and individuals’ actions that may be taken in response to an epidemic or pandemic (including restrictions on travel, transport and workforce pressures, and deferrals or postponements of elective procedures); the impact of such a crisis, and actions taken in response thereto, on global and regional economies, travel and economic activity; the availability of federal, state, local or non-U.S. funding programs; general economic uncertainty in key global markets and financial market volatility; global economic conditions and levels of economic growth; and the timing and pace of recovery as such a crisis subsides, which could be impacted by a number of factors, including limited provider capacity to perform procedures using our products that were deferred as a result of the epidemic or pandemic.
Paragraph 42 · 30% changed Every version of it
In addition, in 2019, the attorneys general of 15 states and the District of Columbia sent a letter to the EPA urging that the EPA promptly propose and finalize stricter standards for ethylene oxide emissions. Subsequently, the EPA solicited information and comments from the public on proposed revisions to regulations regarding ethylene oxide emissions and collected information from commercial sterilizers about ethylene oxide sterilization processes and emissions. In April 2023, the EPA released a proposed rule under the Clean Air Act that would require commercial sterilizers to install pollution control equipment to reduce ethylene oxide emissions and implement methods to continuously monitor emissions and report results to the EPA. In April 2024, the EPA issued the final version of the rule, establishing new standards for ethylene oxide emissions for commercial sterilizers. Sterilizers must comply with the new standards by April 6, 2026, or April 5, 2027, depending on certain characteristics of existing operations, or upon startup for new operations. Failure of our contract sterilizers to achieve compliance with the final rule by the applicable deadline would significantly impair our ability to provide sufficient quantities of sterilized products to our customers and compel us to seek sterilization alternatives that do not entail the use of ethylene oxide. We cannot assure that we would be able to identify such alternatives. In the event we were to experience any disruptions in our ability to sterilize our products, whether due to capacity constraints or regulatory or other impediments (including, among other things, regulatory initiatives directed generally to sterilization facilities that utilize ethylene oxide), or we are unable to transition to alternative facilities in a timely or cost effective manner in the event one or more of the facilities we use is affected, we could experience a material adverse impact with respect to our results of operations and financial condition.
Paragraph 41 · 28% changed Every version of it
In addition, in 2019, the attorneys general of 15 states and the District of Columbia sent a letter to the EPA urging that the EPA promptly propose and finalize stricter standards for ethylene oxide emissions. Subsequently, the EPA solicited information and comments from the public on proposed revisions to regulations regarding ethylene oxide emissions and collected information from commercial sterilizers about ethylene oxide sterilization processes and emissions. In April 2023, the EPA released a proposed rule under the Clean Air Act that would require commercial sterilizers to install pollution control equipment to reduce ethylene oxide emissions and implement methods to continuously monitor emissions and report results to the EPA. In April 2024, the EPA issued the final version of the rule, establishing new standards for ethylene oxide emissions for commercial sterilizers. Sterilizers must comply with the new standards by April 6, 2026, or April 5, 2027, depending on certain characteristics of existing operations, or upon startup for new operations. Failure of our contract sterilizers to achieve compliance with the final rule by the applicable deadline would significantly impair our ability to provide sufficient quantities of sterilized products to our customers and compel us to seek sterilization alternatives that do not entail the use of ethylene oxide. We cannot assure that we would be able to identify such alternatives. In the event we were to experience any disruptions in our ability to sterilize our products, whether due to capacity constraints or regulatory or other impediments (including, among other things, regulatory initiatives directed generally to sterilization facilities that utilize ethylene oxide), or we are unable to transition to alternative facilities in a timely or cost effective manner in the event one or more of the facilities we use is affected, we could experience a material adverse impact with respect to our results of operations and financial condition.
Paragraph 38 · 28% changed Every version of it
Further, even if our enhanced reliance in the proposed separation is completed, wake of the disposition of the Acute Care, Interventional Urology and OEM businesses on a smaller suite of existing products and on future products may pose risks to our growth, and following the transactions, we cannot assure you that each separate company will be successful. Completion of the separation will result in independent public companies that are smaller, a less diversified companies, company than we are today, with a more limited businesses concentrated business. If the financial contribution from remaining legacy products and other products that we may acquire or develop in their respective verticals than Teleflex is today. As a result, each company will the future fails to replace lost contribution from the Acute Care, Interventional Urology and OEM businesses, or otherwise fail to meet expectations, our business, cash flows and results of operations could be adversely affected. We may be more vulnerable to changing market conditions, which could have a material adverse effect on its our business, financial condition and results of operations. In addition, the our diversification of revenues, costs and cash flows will diminish, such that each company’s our results of operations, cash flows, working capital, effective tax rate and financing requirements may be subject to increased volatility, and each company’s our ability to fund capital expenditures and investments, pay dividends and meet debt obligations and other liabilities may be diminished. In addition, we may experience difficulty accessing, or reduced access to, the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade. Each company will also incur one-time and ongoing costs, including costs of operating as independent companies, that the separated businesses will no longer be able to share. In addition, Further, until the market has fully analyzed the values value of the separate companies, our newly focused company, the price of our common stock may experience volatility, and our common stock of the new company may experience volatility. Our common stock or the common stock of the new company may not match some holders’ investment strategies or meet the minimum criteria for inclusion in stock market indices or portfolios, which could cause certain investors to sell their shares, which could in turn lead to declines in the trading price of such stock. As a result of any of the foregoing or other risks, the combined value of the common stock of the two publicly traded companies may be less than what the value of our common stock would have been absent the separation.
Paragraph 126 · 27% changed Every version of it
We are not restricted from issuing additional shares of our common stock or other instruments convertible into our common stock. As of December 31, 2024, we had outstanding approximately 46.3 million shares of our common stock, options to purchase 1.4 million shares of our common stock (of which approximately 1.1 million were vested as of that date), restricted stock units covering 0.2 million shares of our common stock (which are expected to vest over the next three years), performance stock units covering a maximum of 111,696 shares of our common stock (which are expected to vest over the next three years and depend on our performance with regard to specified financial measures and market performance of our common stock compared to designated public companies) and 38 shares of our common stock to be distributed from our deferred compensation plan. As of December 31, 2024, 3.6 2025, 3.2 million shares of our common stock remained available for future issuance under our 2023 Stock Incentive Plan. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price for our common stock.
Paragraph 19 · 23% changed Every version of it
Furthermore, our facilities are subject to periodic inspection by the FDA and other federal, state and foreign government authorities, which require manufacturers of medical devices to adhere to certain regulations, including the FDA’s QSR, which requires, among other things, periodic audits, design controls, quality control testing and documentation procedures, as well as complaint evaluations and investigation. In addition, any facilities assembling kits that include drug components and are registered as drug repackaging establishments are also subject to current good manufacturing practices requirements for drugs. The FDA also requires the reporting of certain adverse events and product malfunctions and requires the reporting of certain recalls or other field safety corrective actions for medical devices. Issues identified through such inspections and reports may result in FDA enforcement action through any of the actions discussed above. Moreover, issues identified through such inspections and reports may require significant resources to resolve.
Paragraph 3 · 22% changed Every version of it
The medical device industry is highly competitive. We compete with many domestic and foreign medical device companies ranging from small start-up enterprises that might sell only a single or limited number of competitive products or compete only in a specific market segment, to companies that are larger and more established than us, have a broad range of competitive products, participate in numerous markets and have access to significantly greater financial and marketing resources than we do. We also face competition from providers of alternative medical therapies, such as pharmaceutical companies. For example, though their long-term impact remains uncertain, the increased use and the recent FDA approval of glucagon-like peptide 1 ("GLP-1") products for the treatment of chronic weight management has impacted the demand for bariatric surgery procedures and our Titan SGS product line acquired as part of our 2022 acquisition of Standard Bariatrics Inc.
Paragraph 125 · 22% changed Every version of it
We are not restricted from issuing additional shares of our common stock or other instruments convertible into our common stock. As of December 31, 2024, 2025, we had outstanding approximately 46.3 44.2 million shares of our common stock, options to purchase 1.4 1.3 million shares of our common stock (of which approximately 1.1 0.9 million were vested as of that date), restricted stock units covering 0.2 million shares of our common stock (which are expected to vest over the next three four years), performance stock units covering a maximum of 111,696 148,807 shares of our common stock (which are expected to vest over the next three years and depend on our performance with regard to specified financial measures and market performance of our common stock compared to designated public companies) and 38 shares of our common stock to be distributed from our deferred compensation plan. As of December 31, 2024, 3.6 million shares of our common stock remained available for future issuance under our 2023 Stock Incentive Plan. We cannot predict the size of future issuances or the effect, if any, that they may have on the market price for our common stock.

MD&A

131 paragraphs · 24 new · 76 reworded · 27 gone · 10-K Feb 27, 2026 against Feb 28, 2025
New paragraph Reworded (5% of its words or more) Same or nearly
Paragraph 15 · 50% changed
Our goodwill impairment testing is performed annually during We test the fourth quarter recoverability of each fiscal year in addition to periods where changes in long-lived assets whenever events or circumstances indicate that the carrying value of our goodwill assets an asset may not be recoverable. During the second first quarter of 2024, 2025, we identified indicators of a potential impairment related to the long-lived assets associated with our Interventional Urology North America reporting unit (the “IU reporting unit”), included within our Americas operating segment. Titan SGS asset group, which primarily consists of intangible assets. The indicators of a potential impairment primarily arose from lower than anticipated expected sales results from of our UroLift Titan SGS product line (“UroLift"), primarily and anticipated continuing reduced demand for bariatric surgery procedures in future periods, driven by the adverse impact growing adoption of persistent end-market challenges within the U.S. office site of service. GLP-1 products. We performed a quantitative impairment test recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates, and concluded that the undiscounted cash flows of the reporting unit using both Titan SGS product line exceeded the income and carrying value of the market approaches, and related assets by approximately 10%. Accordingly, no impairment to goodwill was recognized in during the first quarter of 2025 related to the Titan SGS asset group. During the second quarter of 2024 as 2025, the fair value of the reporting unit exceeded the carrying value. During the third quarter of 2024, the IU reporting unit Titan SGS product line performed largely in line with the forecast used in the second first quarter 2024 quantitative fair value 2025 recoverability test.
Paragraph 59 · 50% changed
Asia operating profit The decrease in income from discontinued operations for the year ended December 31, 2023 increased $16.3 million, or 15.5%, 2024, compared to the prior year, which year was primarily attributable driven by a $240.0 million non-tax deductible goodwill impairment charge related to the Interventional Urology North America reporting unit, partially offset by an increase in gross profit resulting from price increases and higher sales, partially offset driven by unfavorable fluctuations in foreign currency exchange rates and an increase in sales expenses to support higher increased intra-aortic balloon pump sales.
Paragraph 45 · 48% changed
During the fourth first quarter of 2024, 2026, in connection with the Strategic Divestitures, we initiated the "2024 restructuring plan," a new strategic multi-year restructuring plan aimed at optimizing intended to align our global organizational structure and supply chain infrastructure amongst our remaining businesses. The plan is designed to eliminate stranded costs, streamline global operations, reducing costs and enhancing efficiencies across improve our business lines long-term cost structure, primarily through workforce reductions and includes capital assets rationalization. These actions, some of which we expect to occur upon exit of the relocation of select office administrative operations. transition services agreements and other arrangements negotiated in connection with the Strategic Divestitures, are expected to be substantially completed by mid-2028. We estimate that we will incur aggregate pre-tax restructuring and restructuring related charges in connection with the 2024 restructuring plan of $9 $31 million to $11 $37 million. The actions under We expect substantially all the 2024 restructuring plan and restructuring related charges to result in future cash outlays, of which, an estimated $15 million to $19 million are expected to be substantially completed by the end of 2025. occur during 2026. We began realizing plan-related savings in the fourth quarter of 2024 and expect to achieve annual pre-tax savings of $9 $48 million to $11 $52 million in connection with the Strategic Divestitures restructuring plan once the plan it is fully implemented. implemented and we expect to begin realizing a portion of these plan-related savings in 2026.
Paragraph 93 · 47% changed
Net cash provided by operating activities from continuing operations was $638.3 $96.7 million during 2024, 2025 and $511.7 $301.9 million during 2023. 2024. The $126.6 $205.2 million increase decrease was primarily attributable to favorable unfavorable operating results, surplus plan assets results and working capital. The unfavorable changes in working capital were primarily driven by a net increase in accounts receivable resulting from an increase in receivables associated with the VI Business (as we did not acquire certain trade receivables) and the prior period inflow from proceeds received from the TRIP termination included within prepaid expenses and other assets, a decrease in assets. Net cash outflows provided by operating activities from inventories as we continue to moderate our inventory levels continuing operations was also unfavorably impacted by recently enacted tariffs and a decrease in cash outflows from accounts payable acquisition and accrued integration expenses stemming primarily from lower payments associated with our restructuring plans. The increases in net cash provided from operating activities were partially offset by higher tax payments. the VI Business.
Paragraph 103 · 46% changed
Concurrent with the execution of the agreement to acquire the VI Business, we entered into an amendment to our Third Amended and Restated Credit Agreement (the “Credit Agreement”), which, among other things, (a) provides for a delayed draw term loan facility in an aggregate principal amount of $500 million, which will be available to be drawn on the date on which we consummate the VI Business acquisition and (b) permits us to borrow up to $550 million under the revolving facility provided for under the Credit Agreement on a limited condition basis on the date on which the VI Business acquisition is consummated. Borrowings under the delayed draw term loan will bear interest at a rate per annum equal to the applicable margin plus, at our option, either (1) the highest of (i) the “Prime Rate” in the U.S. last quoted by The Wall Street Journal, (ii) 0.50% above the greater of the federal funds rate and the rate comprised of both overnight federal funds and overnight eurodollar transactions denominated in dollars and (iii) 1.00% above the Term SOFR Rate for a one month interest period, plus an applicable margin ranging from 0.125% to 1.00%, in each case subject to adjustments based on our total net leverage ratio or (2) a Term Secured Overnight Financing Rate (“SOFR”) rate (which includes a credit spread adjustment of 10 basis points). The applicable margin for borrowings under the delayed draw term loan range from 1.125% to 2.00% for SOFR borrowings and from 0.125% to 1.00% for base-rate borrowings, in each case, depending on, at our election, either (x) our public corporate family rating or (y) our consolidated total net leverage ratio, in each case, based on the most recently ended fiscal quarter. The obligations under the delayed draw term loan will be guaranteed and secured on the same basis as the facilities provided for under the Credit Agreement. The delayed draw term loan will not amortize and will mature on the earlier of (x) the date that is two years after the date on which such loans are funded and (y) the maturity date for the revolving facility provided for under the Credit Agreement.
Paragraph 30 · 44% changed
Selling, general and administrative expenses increased $65.4 $45.7 million for the year ended December 31, 2024, 2025, compared to the prior year period, year, primarily due attributable to a benefit recognized $92.2 million in the prior year period resulting from decreases in the estimated fair value of our contingent consideration liabilities, whereas, in the current period, we recognized an expense due to increases in these liabilities. Additionally, higher operating operating, integration and amortization expenses incurred by associated with the acquired Palette business VI Business, the impact of unfavorable fluctuations in foreign currency exchange rates related to operating activities and higher IT related costs that were costs, primarily driven by our implementation ongoing development of a new ERP solution contributed solution. The increases in selling, general and administrative expenses were partially offset by an $82.2 million benefit from non-designated foreign currency forward contracts designed to hedge against the overall increase. cash consideration for the VI Business.
Paragraph 27 · 41% changed
For the year ended December 31, 2024, 2025, gross margin increased 50 decreased 480 basis points, or 0.9%, 7.9%, compared to the prior year period, year, primarily due to the favorable adverse impact from the amortization of gross margin attributed the step-up in carrying value of inventory and intangible assets recognized in connection with the VI Business acquisition, the adverse impact from recently enacted tariffs, an increase in logistics and distribution costs and continued cost inflation from macro-economic factors, specifically with respect to acquired labor and divested businesses, price increases and the benefits from cost improvement initiatives. raw materials. The increases decrease in gross margin were was partially offset by the unfavorable favorable impact from an increase a decrease in our reserves related to the Italian payback measure, continued measure.
Paragraph 68 · 40% changed
EMEA increase in net revenues for the year ended December 31, 2024 increased $31.8 million, or 5.4%, compared to the prior year, which was primarily attributable to a $25.8 million increase in sales volumes of existing products and price increases, partially offset by the unfavorable impact from an increase in our reserves related to the Italian payback measure.

A paragraph is matched with the one last year that shares the most of its words; under half in common makes it new. The paragraphs shown are the 8 reworded the most in each section.

The paragraph that changed most in each section

The redline

Marked against last year's 10-K: cut words struck through, new words highlighted.

Risk Factors262 words changed in this paragraph; it is 56% similar to last year's version.
Further, even if our enhanced reliance in the proposed separation is completed, wake of the disposition of the Acute Care, Interventional Urology and OEM businesses on a smaller suite of existing products and on future products may pose risks to our growth, and following the transactions, we cannot assure you that each separate company will be successful. Completion of the separation will result in independent public companies that are smaller, a less diversified companies, company than we are today, with a more limited businesses concentrated business. If the financial contribution from remaining legacy products and other products that we may acquire or develop in their respective verticals than Teleflex is today. As a result, each company will the future fails to replace lost contribution from the Acute Care, Interventional Urology and OEM businesses, or otherwise fail to meet expectations, our business, cash flows and results of operations could be adversely affected. We may be more vulnerable to changing market conditions, which could have a material adverse effect on its our business, financial condition and results of operations. In addition, the our diversification of revenues, costs and cash flows will diminish, such that each company’s our results of operations, cash flows, working capital, effective tax rate and financing requirements may be subject to increased volatility, and each company’s our ability to fund capital expenditures and investments, pay dividends and meet debt obligations and other liabilities may be diminished. In addition, we may experience difficulty accessing, or reduced access to, the capital markets or increased cost of borrowings, including as a result of a credit rating downgrade. Each company will also incur one-time and ongoing costs, including costs of operating as independent companies, that the separated businesses will no longer be able to share. In addition, Further, until the market has fully analyzed the values value of the separate companies, our newly focused company, the price of our common stock may experience volatility, and our common stock of the new company may experience volatility. Our common stock or the common stock of the new company may not match some holders’ investment strategies or meet the minimum criteria for inclusion in stock market indices or portfolios, which could cause certain investors to sell their shares, which could in turn lead to declines in the trading price of such stock. As a result of any of the foregoing or other risks, the combined value of the common stock of the two publicly traded companies may be less than what the value of our common stock would have been absent the separation.

Source: Item 1A, 10-K 0000096943-26-000019 vs Item 1A, 10-K 0000096943-25-000031

Legal Proceedings226 words changed in this paragraph; it is 65% similar to last year's version.
Other: In 2015, the Italian parliament enacted legislation that, among other things, imposed a “payback” measure on medical device companies that supply goods and services to the Italian National Healthcare System. Under the measure, companies are required to make payments to the Italian government if medical device expenditures in a given year exceed regional expenditure ceilings established for that year. The payment amounts are calculated based on the amount by which the regional ceilings for the given year were exceeded. Considerable uncertainty exists related to the enforceability of and implementation process for the payback law. In response to decrees issued by the Italian Ministry of Health, the various Italian regions issued invoices to medical device companies, including Teleflex, under the payback measure in the fourth quarter of 2022 seeking payment with respect to excess expenditures for the years 2015 through 2018. Following the issuance of the invoices, we and numerous other medical device companies filed appeals with the Italian administrative courts challenging the enforceability of the payback measure, primarily on the basis that the law was unconstitutional. The Italian administrative courts referred the question regarding the constitutionality of the law to the Italian Constitutional Court, which in July 2024, issued a ruling upholding the law as constitutional. In August 2025, the Italian parliament enacted a modification to the previously enacted legislation that reduced the payment amounts due from the affected companies, including Teleflex, to approximately 25 % of the amounts originally invoiced for the years 2015 through 2018. Payment of the reduced amount precludes the pursuit of further legal action related to the obligation to pay the amounts relating to such years. During the year ended December 31, 2024 third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized increases to a $ 23.7 million decrease in our reserve and during the third quarter of 2025. The decrease in our reserve resulted in a corresponding reductions increase to revenue of $ 22.1 million. The increase in reserve for the year ended December 31, 2024 included 2025, of which $ 13.8 9.0 million pertaining pertains to prior years stemming from the July 2024 ruling. periods within continuing operations. As of December 31, 2024, 2025, our reserve related to this matter is was $ 35.7 19.4 million. Following the ruling of the Italian Constitutional Court, the appeal before the Italian administrative court will proceed with respect to the remaining legal arguments asserted by the appellants to the enforceability of the payback law.

Source: Item 3, via Note 17 – Commitments and contingent liabilities, 10-K 0000096943-26-000019 vs Item 3, via Note 17 – Commitments and contingent liabilities, 10-K 0000096943-25-000031

MD&A206 words changed in this paragraph; it is 42% similar to last year's version.
Our goodwill impairment testing is performed annually during We test the fourth quarter recoverability of each fiscal year in addition to periods where changes in long-lived assets whenever events or circumstances indicate that the carrying value of our goodwill assets an asset may not be recoverable. During the second first quarter of 2024, 2025, we identified indicators of a potential impairment related to the long-lived assets associated with our Interventional Urology North America reporting unit (the “IU reporting unit”), included within our Americas operating segment. Titan SGS asset group, which primarily consists of intangible assets. The indicators of a potential impairment primarily arose from lower than anticipated expected sales results from of our UroLift Titan SGS product line (“UroLift"), primarily and anticipated continuing reduced demand for bariatric surgery procedures in future periods, driven by the adverse impact growing adoption of persistent end-market challenges within the U.S. office site of service. GLP-1 products. We performed a quantitative impairment test recoverability test, utilizing an updated long-term forecast reflecting higher uncertainty of revenue growth in future periods compared to previous estimates, and concluded that the undiscounted cash flows of the reporting unit using both Titan SGS product line exceeded the income and carrying value of the market approaches, and related assets by approximately 10%. Accordingly, no impairment to goodwill was recognized in during the first quarter of 2025 related to the Titan SGS asset group. During the second quarter of 2024 as 2025, the fair value of the reporting unit exceeded the carrying value. During the third quarter of 2024, the IU reporting unit Titan SGS product line performed largely in line with the forecast used in the second first quarter 2024 quantitative fair value 2025 recoverability test.

Source: Item 7, 10-K 0000096943-26-000019 vs Item 7, 10-K 0000096943-25-000031

Accounting Policies113 words changed in this paragraph; it is 68% similar to last year's version.
Revenue recognition: We primarily generate revenue from the sale of medical devices including single use disposable devices and, to a lesser extent, reusable devices, instruments and capital equipment. Revenue is recognized when obligations under the terms of a contract with our customer are satisfied; this occurs upon the transfer of control of the products. Generally, transfer of control to the customer occurs at the point in time when our products are shipped from the manufacturing or distribution facility. For the OEM (Original Equipment Manufacturer and Development Services) product category, included within our Americas segment, most revenue is recognized over time because OEM generates revenue from the sale of custom products that have no alternative use and we have an enforceable right to payment to the extent that performance has been completed. We market and sell products through our direct sales force and distributors to customers within the following end markets: (1) hospitals and healthcare providers; (2) other medical device manufacturers; and (3) home care providers, which represented 87 %, 11 % and 2 % of our consolidated net revenues, respectively, for the year ended December 31, 2024. providers. Revenue is measured as the amount of consideration we expect to receive in exchange for transferring goods. With respect to the custom products sold in the OEM, revenue is measured using the units produced output method. Payment is generally due 30 days from the date of invoice.

Source: 10-K text, Note 1 – Summary of significant accounting policies, 10-K 0000096943-26-000019 vs 10-K text, Note 1 – Summary of significant accounting policies, 10-K 0000096943-25-000031

Sentences and paragraphs added, removed or reworded

Every change, by type

Sentences and paragraphs of TFX's Risk Factors and MD&A, 10-K Feb 27, 2026 against 10-K Feb 28, 2025. Each links to the text at sec.gov.

Quiet changes are sentences kept from last year with one to four words changed, at least one of them a hedge, a modal or a qualifier (may, could, will, not, significant, material…). A year or date rolling forward is not counted.

The full word list

adverse, adversely, all, although, anticipate, anticipates, any, approximately, believe, believes, can, cannot, certain, could, expect, expects, generally, however, if, intend, intends, largely, likely, many, material, materially, may, might, most, must, never, no, not, possible, primarily, probable, should, significant, significantly, some, substantial, substantially, unlikely, will, would

AddedRisk Factors
In February 2025, we announced our intention to undertake a strategic transformation of the organization. In accordance with this strategy, on December 9, 2025, with the simultaneous execution of definitive agreements to sell our Acute Care and Interventional Urology businesses to Intersurgical® Ltd and the OEM business to Montagu and Kohlberg (collectively referred to as the "Strategic Divestitures"). The combined transaction total of Strategic Divestitures is $2.0 billion in cash, consisting of expected proceeds of approximately $1.5 billion for our OEM business and $530 million for our Acute Care and Interventional Urology businesses. Both transactions, which were approved by our Board of Directors, remain subject to certain closing adjustments, customary regulatory approvals and other closing conditions and are expected to be completed in the second half of 2026.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
However, we can make no assurance that the announced transactions will be consummated on the timeframe contemplated or at all. We will face significant challenges in connection with first consummating, and then managing our business following the Strategic Divestitures. These challenges include, without limitation, obtaining the regulatory approvals necessary for, and satisfying the closing conditions to, the transactions, and the diversion of management’s attention from ongoing business concerns to completing the transactions. Then, both in the period before the transactions are consummated and thereafter, when we are operating a modified business, we may face
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
countries in retaliation, or the impact, if any, that any policy changes could have on our business. Any of the foregoing could have a material adverse effect on our financial condition, results of operations or cash flows.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedRisk Factors
On January 8, 2026, we announced that Stuart Randle, a member of our board of directors, has been appointed Interim President and Chief Executive Officer, succeeding our prior Chairman, President and CEO, and that Dr. Stephen Klasko, at that time our Lead Director, has been named Chairman of the Board. We also announced that the board has engaged a leading executive search firm to assist in a comprehensive search process to identify a permanent CEO. There are a number of risks associated with a CEO transition, any of which may harm us. The market for such positions is competitive, and qualified individuals are in high demand. If we are unable to identify a strong candidate for the position, or if our replacement CEO, interim or permanent, is unsuccessful at leading our company or is unable to articulate and execute our strategy and vision, it could have a material adverse effect on our business, financial condition, results of operations and cash flows. With the change in leadership, there is a risk to retention of other members of our senior management team, as well as to continuity of business initiatives, plans, and strategies through the transition period and if we are unable to execute an orderly transition, our business may be adversely affected.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedRisk Factors
As described more fully in Item 7 and Note 8 to the consolidated financial statements of this Annual Report on Form 10-K, in connection with preparing the financial statements for the year ended December 31, 2024, we determined that the carrying value of the IU reporting unit exceeded its fair value, and we therefore recognized an impairment charge of $240 million in the goodwill impairment line in the Consolidated Statements of Income. The charge was primarily driven by the recognition of intensifying competition in the industry and sustained revenue short-falls due to persistent end-market challenges. We anticipate this combination of price and volume challenges is likely to continue to impact future growth rates of the IU reporting unit. Continued adverse changes to macroeconomic conditions or our earnings forecasts would lead to additional goodwill impairment charges and such charges would negatively affect our results of operations.
Read it in 10-K Feb 28, 2025 at sec.gov
Show the other 59
RemovedRisk Factors
Many of our key products are manufactured at or distributed from single locations, and the availability of alternate facilities is limited. If operations at one or more of our facilities is suspended due to natural disasters or other events, including, without limitation, those due to climate change, we may not be able to timely manufacture or
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
We recently announced the proposed separation of Urology, Acute Care and OEM businesses. We may encounter challenges to executing the proposed separation of our Urology, Acute Care and OEM businesses on the terms and within the timeframe we announced, or at all. The separation will be subject to the satisfaction of a number of customary conditions, including, but not limited to, the final approval from the Company’s Board of Directors, the filing and effectiveness of a registration statement on Form 10, the receipt of a favorable Internal Revenue Service ruling and tax opinion the Company’s tax advisor with respect to the tax-free nature of the separation, the satisfactory completion of financing arrangements and the receipt of any necessary regulatory approvals. The failure to satisfy any of the required conditions could delay the completion of the proposed separation for a significant period of time or prevent it from occurring at all. Additionally, it is complex in nature, and unanticipated developments or changes, including disruptions in general market conditions, changes in law or challenges in executing the separation of the two businesses, may affect our ability to complete the separation on the terms or on the timeline we announced, or at all. The terms and conditions of the required regulatory authorizations and consents that are granted, if any, may also impose requirements, limitations or costs, or place restrictions on the conduct of the independent companies or impact our ability to complete the separation on the terms or timeline we announced, or at all.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Although we intend for the proposed separation to be tax-free to the Company’s stockholders for U.S. federal income tax purposes, there can be no assurance that the proposed separation will qualify for such treatment. The IRS ruling and opinion described above will be each based upon various factual representations and assumptions, as well as certain undertakings made by the Company and the new independent company. If any of these factual representations or assumptions are, or become, untrue or incomplete in any material respect, an undertaking is not complied with, or the facts upon which the ruling and opinion are based are materially different from the actual facts relating to the separation, reliance on the ruling and opinion may be jeopardized. If the separation was ultimately determined to be taxable for U.S. federal income tax purposes, we would incur a significant tax liability, while the distribution of shares of the new independent company to the Company’s stockholders would become taxable to them for U.S. federal income tax purposes and the new independent company could incur income tax liabilities as well. In addition, even if the separation is tax-free for U.S. federal income tax purposes, the Company and the new independent company may incur state, local, non-U.S. and/or non-income taxes in connection with the separation, including as a result of the incorporation of the OECD’s Pillar Two global minimum tax framework into local country tax laws, which taxes may be significant.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedRisk Factors
Our businesses will face material challenges in connection with the proposed separation. These challenges include, without limitation, the diversion of management’s attention from ongoing business concerns; appropriately allocating assets and liabilities among the companies to be separated in the proposed separation, particularly given
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedRisk Factors
As of December 31, 2024, 2025, we had outstanding approximately 46.3 44.2 million shares of our common stock, options to purchase 1.4 1.3 million shares of our common stock (of which approximately 1.1 0.9 million were vested as of that date), restricted stock units covering 0.2 million shares of our common stock (which are expected to vest over the next three four years), performance stock units covering a maximum of 111,696 148,807 shares of our common stock (which are expected to vest over the next three years and depend on our performance with regard to specified financial measures and market performance of our common stock compared to designated public companies) and 38 shares of our common stock to be distributed from our deferred compensation plan.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Our Further, until the market has fully analyzed the value of our newly focused company, the price of our common stock or the may experience volatility, and our common stock of the new company may not match some holders’ investment strategies or meet the minimum criteria for inclusion in stock market indices or portfolios, which could cause certain investors to sell their shares, which could in turn lead to declines in the trading price of such stock.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
While we have realized some efficiencies from these initiatives, we may not realize the benefits of these or future initiatives to the extent we anticipated. anticipated, particularly with respect to initiatives involving contingencies that are not completely within our control, such as the completion of acquisitions or divestitures.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Furthermore, our issuance of shares upon the exercise of some or all of the outstanding stock options, as well as the vesting of restricted stock units and some or all of the performance stock units will dilute the ownership interests of existing stockholders, and the subsequent sale in the public market of such shares of our common stock could adversely affect prevailing market prices of our common stock.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Failure to submit required information may result in civil monetary penalties for each payment, transfer of value or ownership or investment interests not reported in an annual submission, up to an aggregate of $150,000 per year (and up to an aggregate of $1 million per year for “knowing failures”), as adjusted annually for inflation.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
However, these effects could have an adverse impact on our liquidity, capital resources, operations, business results and those of the third parties on which we rely, and such impact could be material.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
We cannot predict what additional actions may ultimately be taken by the U.S. or other governments with respect to tariffs or trade relations, what products may be subject to such actions (including subject to U.S. export control restrictions), or what actions may be taken by the other countries in retaliation, or the impact, if any, that any policy changes could have on our business.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In this regard, if, at the expiration or earlier termination of our swap agreements, the U.S. dollar to euro Euro or to Swiss Franc exchange rate has rates have declined by 10% from the rate in effect at the inception of our agreements, we would be required to pay approximately $75 $100 million or $60 million, respectively, to the counterparties in respect of the notional settlement.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
In addition, for the years ended December 31, 2024, 2023 2025, 2024 and 2022, 38%, 37% 2023, 41%, 36% and 36%, 35%, respectively, of our net revenues from continuing operations (based on the Teleflex entity generating the sale) were derived from operations outside the U.S.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
As a result, However, even if both of the proposed separation is Strategic Divestitures are completed, it we may not achieve some or all of the anticipated strategic, financial, operational or other benefits in the expected timeframe, or at all, which could adversely impact our business, results of operations or financial condition.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedRisk Factors
Our In addition to the strategic transformation we announced in February 2025, our strategic initiatives include making significant investments designed to achieve revenue growth and to enable us to meet or exceed margin improvement targets.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
Under our cross-currency swap agreements, a meaningful decline in the U.S. dollar to euro certain exchange rate rates could have a material adverse effect on our cash flows.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
We have entered into cross-currency swap agreements with several financial institutions to hedge against the effect of variability in the U.S. dollar to euro certain exchange rate. rates.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesRisk Factors
In the event of a significant decline in the U.S. dollar to euro certain exchange rate, rates, our payment obligations to the counterparties could have a material adverse effect on our cash flows.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In February 2025, we announced our intention to undertake a strategic transformation of the organization. In accordance with this strategy, on December 9, 2025, we announced that we entered into definitive agreements to sell our Acute Care and Interventional Urology (also referred to as "IU") businesses to Intersurgical® Ltd and our OEM business to Montagu and Kohlberg (collectively referred to as the "Strategic Divestitures"). The combined total consideration from the Strategic Divestitures is $2.0 billion in cash, consisting of expected proceeds of approximately $1.5 billion for our OEM business and $530 million for our Acute Care and IU businesses. Both transactions, which were approved at the same time by our Board of Directors, remain subject to certain closing adjustments, customary regulatory approvals and other closing conditions and are expected to be completed in the second half of 2026. We expect to receive net after‑tax proceeds of approximately $1.8 billion upon the completion of both sales. We intend to use the net proceeds primarily to return capital to shareholders through share repurchases and pay down debt, enhancing our financial flexibility to support our growth strategy.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In connection with the Strategic Divestitures, we have negotiated transition services agreements and other arrangements intended to govern ongoing activities between Teleflex and the respective buyers following the closing dates of the transactions, including interim operating model arrangements and manufacturing and supply services. Although the material terms of these agreements have been substantially determined, they remain subject to finalization and execution. We expect to complete and execute these agreements at the close of each transaction.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The Strategic Divestitures represent a single plan to exit certain product categories that, in aggregate, meet accounting requirements to be classified as discontinued operations and held for sale as of December 31, 2025. Information provided herein is presented on a continuing operations basis to reflect the impact of the Strategic Divestitures, unless otherwise indicated. For additional information regarding the Strategic Divestitures, refer to Note 5 to the consolidated financial statements included in this Annual Report on Form 10-K.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
On January 8, 2026, we announced the departure of our Chairman, President and Chief Executive Officer, Liam J. Kelly, and the appointment of Stuart A. Randle as Interim President and Chief Executive Officer. In connection with Mr. Kelly’s departure as President and Chief Executive Officer, the Board appointed Stephen K. Klasko, M.D., a current independent director who had been serving as our Lead Director, to serve as the independent Chair of the Board.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
On June 30, 2025, the first day of the third fiscal quarter of 2025, we completed the acquisition of the VI business for a net initial cash payment of €704.3 million, or $825.2 million, subject to certain working capital and other customary adjustments. Borrowings under the delayed draw term loan, discussed in Note 11 and within the Liquidity and Capital Resources section below, and our revolving credit facility were utilized to finance the
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
In connection with the acquisition, we also entered into several ancillary agreements with BIOTRONIK SE & Co. KG to help facilitate business continuity and the integration of the business. These agreements primarily relate to transition support and distribution services and have varying durations extending up to 36 months.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
During the third quarter of 2025, we identified additional indicators of a potential impairment related to the Titan SGS asset group due to lower than expected sales growth during the period and a further downward revision to sales forecasts compared to the forecast utilized in our first quarter 2025 impairment analysis. As a result, in connection with the preparation of the financial statements for the third quarter of 2025, we performed a recoverability test and as a result, we determined that the carrying value of the asset group was not fully recoverable. We subsequently recognized an impairment charge of $100.0 million, representing the amount by which the carrying value of the asset group exceeded its estimated fair value, as determined utilizing the income approach. After the recognition of the impairment charge, the remaining carrying value of the intangible assets of the Titan SGS asset group was $25.1 million as of the end of the third quarter of 2025. Despite the downward revision to sales forecasts, we continue to anticipate revenue growth from the Titan SGS asset group in future periods.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
such years. During the third quarter of 2025, we remitted payment to the related regions to settle the years 2015 through 2018. As a result of the modification in the legislation, along with an adjustment to our calculation of the reserves related to years 2019 through 2025, we recognized a $23.7 million decrease in our reserve during the third quarter of 2025. The decrease in our reserve resulted in a corresponding increase to revenue for the year ended December 31, 2025, of which $9.0 million pertains to prior periods within continuing operations. As of December 31, 2025, our reserve related to this matter was $19.4 million.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
The healthcare industry has been, and may continue to be, adversely affected by government-led initiatives intended to reduce healthcare product costs, such as China’s volume-based procurement programs, which have impacted and may further impact our results. These initiatives have also affected, and may continue to affect, the demand for our products.
Read it in 10-K Feb 27, 2026 at sec.gov
AddedMD&A
We have implemented various measures designed to mitigate the future impacts of these factors impacting our business, which include tariff specific measures such as supply chain optimization strategies, adjustments to chain-of-custody protocols, and increasing the proportion of USMCA-compliant products in our portfolio, in addition to pricing actions. Nevertheless, additional changes to proposed or enacted tariffs, including those resulting from the February 2026 ruling from the U.S. Supreme Court and any related developments that may follow from it, could materially impact our business, including gross margins and cash flows. The ultimate effect of tariffs and trade policy changes on our results of operations and cash flows will depend on several factors, including the timing, scale, scope, and nature of any tariffs or policies implemented, as well as any associated retaliatory measures.
Read it in 10-K Feb 27, 2026 at sec.gov
RemovedMD&A
In connection with preparing the financial statements for the year ended December 31, 2024, we performed our annual impairment test for goodwill and determined that the carrying value of the IU reporting unit exceeded its fair value. Consequently, we recognized a non-cash impairment charge of $240 million in the goodwill impairment line in the Consolidated Statements of Income. The charge was primarily driven by updates to our UroLift forecast, done as part of our annual operating plan process, which reflects management's expectations of a prolonged period of subdued revenue growth due to persistent end-market challenges and changes in competitive pressures in the short to mid-term. Moreover, we anticipate that challenges related to a combination of price, mainly within the office site of service, and volume, will likely continue to impact growth rates.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
As of December 31, 2024, goodwill of the IU reporting unit was $403.9 million after the impairment charge. We estimated the fair value of the reporting unit using both the income and the market approaches. The more significant judgments and assumptions in determining the fair value of the IU reporting unit for our 2024 impairment assessments included the revenue growth rates, the projected operating margins and the discount rate. The quantitative assessment utilized a discount rate of 10.75%. A hypothetical 1% increase in our discount rate estimate used to determine the fair value of the estimated future cash flows would result in an additional impairment charge of $95.0 million.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In 2023, we began the execution of a plan to terminate the Teleflex Incorporated Retirement Income Plan (the “TRIP”), a U.S. defined benefit pension plan. The TRIP is subject to Title IV of the Employee Retirement Income Security Act of 1974, as amended (“ERISA”), and, therefore, must be terminated in accordance with the requirements of ERISA and the process governed by the Pension Benefit Guaranty Corporation (the “PBGC”). The termination date of the TRIP was August 1, 2023, which is the date upon which the timing of the requirements for the formal termination process is based. On September 8, 2023, we filed the required notice regarding the TRIP termination with the PBGC. The termination process requires that all TRIP benefits be distributed to participants, beneficiaries and alternate payees or transferred to a group annuity contract or the PBGC. In December of 2023, we made payments to eligible participants, beneficiaries and alternate payees who elected the one-time lump sum distribution option offered in connection with the TRIP termination, resulting in the recognition of a pre-tax settlement charge of $45.2 million.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
In 2024, we purchased a group annuity contract, using TRIP assets, which resulted in the recognition of net pre-tax settlement charges of $132.7 million for the year-ended December 31, 2024. The participants, beneficiaries, and alternate payees whose benefits were transferred to the group annuity contract will each receive from such group annuity contract the full value of their benefit that accrued under the TRIP. The assets in the TRIP Trust exceed the estimated liability for amounts to be transferred to the PBGC for missing participants and beneficiaries (“surplus plan assets”) and as a result, we transferred $43.0 million of the surplus plan assets to a suspense account within the Teleflex 401(k) Savings Plan, a qualified defined contribution plan. These assets are restricted for future use in accordance with our election to use them to fund future employer contributions to participants in the Teleflex 401(k) Savings Plan. The surplus assets contributed to the suspense account remaining as of December 31, 2024 are
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
We anticipate using the new delayed draw term loan along with revolving credit borrowings under the Credit Agreement and cash on hand to finance the VI Business acquisition. For the year ended December 31, 2024, we incurred transaction costs of $11.5 million in connection with the acquisition, which was recognized in selling, general and administrative expenses in the Consolidated Statement of Income. The majority of the transaction costs were recognized in the fourth quarter of 2024.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
On February 27, 2025, we announced our intention to create a new, independently traded public company comprising Urology (consisting of our Interventional Urology and Urology product categories), Acute Care (consisting of our Respiratory product category, the majority of our Anesthesia product category and certain products within our Interventional Access and Surgical product categories) and our OEM businesses. Our Vascular Access product category, most of our products within our Interventional Access and Surgical product categories and the expected acquisition of the VI business will remain with Teleflex. We intend to target the completion of the transaction in the middle of 2026 via a distribution of newly issued shares of the new company to shareholders that is tax-free for U.S. tax purposes. There can be no guarantees that the proposed separation will be completed on the terms and within the timeframe we announced, or at all.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
The healthcare industry has been impacted by shifts in the delivery, or site of service, of healthcare services, staffing shortages at healthcare facilities and government-led initiatives designed to reduce the cost of healthcare products. These factors have impacted and may continue to influence the demand for our products in the future.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
For a discussion of our results of operations comparison for 2023 and 2022, refer to our Annual Report on Form 10-K for the fiscal year ended December 31, 2023 filed on February 23, 2024. Discussion of our reportable segment results of operations comparison for 2023 and 2022 is included below within this Annual Report on Form 10-K to reflect the changes in our segment presentation, which occurred during the fourth quarter of 2024.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
We expect to achieve annual pre-tax savings of $12 million to $14 million once the plan is fully implemented. The impact of product rationalization efforts will partially offset the annual pre-tax savings generated by the plan.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
A significant number of jurisdictions, including EU member states, have enacted legislation to establish a 15% global minimum tax in accordance with both the established Pillar Two framework and guidance subsequently published by the OECD. We considered and analyzed the enacted tax laws and guidance in the jurisdictions relevant to Teleflex, and there are no material impacts to our tax provision for the year ended December 31, 2024. We will continue to evaluate the potential impact of future proposed legislation, enacted legislation, and updated guidance as it becomes available but do not currently expect a material increase to our effective tax rate as a result of the Pillar Two framework.
Read it in 10-K Feb 28, 2025 at sec.gov
RemovedMD&A
During the second half of 2024, we were notified that a large customer within our OEM product category intended to vertically integrate a component that we previously manufactured on their behalf. Additionally, we have begun to experience delays in orders from certain customers as they increasingly focus on managing inventories. We cannot predict with certainty the timing of customer inventory corrections; however, should the current trend of customers more tightly managing their inventory persist, it may adversely impact future results.
Read it in 10-K Feb 28, 2025 at sec.gov
RewordedMD&A
Asia EMEA operating profit for the year ended December 31, 2024 2025 decreased $6.3 $36.3 million, or 5.2%, 71.4%, compared to the prior year, which was primarily attributable to an increase the adverse impact from the amortization of the step-up in sales carrying value of inventory and marketing expenses to support intangible assets recognized in connection with the VI Business acquisition, as well as higher sales, an increase in research operating and development expenses, integration costs of the acquired business and unfavorable fluctuations in foreign currency exchange rates.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Americas net revenues for the year ended December 31, 2023 2025 increased $115.1 $122.3 million, or 6.0%, 10.6%, compared to the prior year, which was primarily attributable to net revenues of $49.0 million generated by the acquired VI Business, a $125.9 $39.0 million increase in sales volumes of existing products, sales of new products, price increases products and, to a lesser extent, net revenues generated by the acquired Palette and Standard Bariatrics businesses, partially offset by an $86.2 million decrease in sales volume of existing products. price increases.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
EMEA net Net revenues for the year ended December 31, 2024 2025 increased $31.8 by $293.2 million, or 5.4%, 17.2%, compared to the prior year, which was primarily attributable due to net revenues of $202.4 million generated by the acquired VI Business, a $25.8 $35.7 million increase in sales volumes of existing products and price increases, partially offset by the unfavorable impact from an increase $24.2 million in our reserves related to the Italian payback measure. sales of new products.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
EMEA net Net revenues for the year ended December 31, 2024 increased $31.8 decreased by $12.9 million, or 5.4%, 0.8%, compared to the prior year, which was primarily attributable due to a $25.8 $75.7 million increase in sales volumes decrease from the 2023 expiration of existing products the manufacturing and price increases, partially offset by supply transition agreement ("MSA") associated with our 2021 Respiratory business divestiture and, to a lesser extent, the unfavorable impact from an increase in our reserves related to the Italian payback measure.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Net cash used in provided by financing activities from continuing operations was $421.9 $611.5 million during 2024, 2025, which primarily consisted of $200.0 $987.0 million in net proceeds from borrowings under our Senior Credit Facility, $300.0 million in repurchases of our common stock under the accelerated share repurchase agreement, a $161.5 million reduction in net borrowings under our Senior Credit Facility and $63.5 $60.3 million in dividend payments. payments, and contingent consideration payments of $15.5 million.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The decrease increase in interest expense for the year ended December 31, 2024, 2025, compared to the prior year was primarily due to a decrease an increase in our the average outstanding debt balance. balance stemming from new borrowings utilized to fund the VI Business acquisition, partially offset by a lower average interest rate resulting from decreases in interest rates associated with our variable interest rate debt instruments.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Americas operating profit for the year ended December 31, 2023 2025 increased $44.1 $42.7 million, or 6.6%, 10.0%, compared to the prior year, which was primarily attributable to an increase in gross profit resulting as a result of higher revenue from higher sales and price increases and a benefit recognized from decreases in our legacy businesses as well as revenues generated by the estimated fair value of our contingent consideration acquired VI Business.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Asia net revenues for the year ended December 31, 2024 2025 increased $16.1 $38.8 million, or 4.7%, 19.2%, compared to the prior year, which was primarily attributable to a $13.0 net revenues of $51.1 million increase in sales volumes of existing products, and revenues generated by the acquisition acquired VI Business, partially offset by price decreases primarily due to the implementation of Palette. volume-based procurement programs in China.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
EMEA net revenues for the year ended December 31, 2024 increased $31.8 $23.3 million, or 5.4%, 7.3%, compared to the prior year, which was primarily attributable to a $25.8 $13.2 million contribution from price increases, an $11.5 million increase in sales volumes of existing products and price increases, partially offset by the unfavorable impact from and, to a lesser extent, an increase in our reserves related to the Italian payback measure. sales of new products.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
The indicators of a potential impairment primarily arose from lower than anticipated expected sales results from of our UroLift Titan SGS product line (“UroLift"), primarily and anticipated continuing reduced demand for bariatric surgery procedures in future periods, driven by the adverse impact growing adoption of persistent end-market challenges within the U.S. office site of service. GLP-1 products.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
For the year ended December 31, 2024, gross margin increased 50 30 basis points, or 0.9%, 0.5%, compared to the prior year period, year, primarily due to the favorable impact of on gross margin attributed to acquired of the 2023 expiration of the MSA associated with our 2021 Respiratory business divestiture, and divested businesses, price increases and the benefits from cost improvement initiatives. increases.
Read it in 10-K Feb 27, 2026 at sec.gov
RewordedMD&A
Asia operating profit for the year ended December 31, 2024 decreased $6.3 $18.7 million, or 5.2%, 29.0%, compared to the prior year, which was primarily attributable to an increase a decrease in gross profit resulting from lower sales and marketing expenses unfavorable impact from product mix, in addition to support higher sales, an increase in research and development expenses, and unfavorable fluctuations in foreign currency exchange rates. sales expenses.
Read it in 10-K Feb 27, 2026 at sec.gov
Quiet changesMD&A
The acquisition will include adds a broad suite of coronary and peripheral medical devices, such as drug-coated balloons, stents, and balloon catheters, which will complement our interventional product portfolio.
Read it in 10-K Feb 27, 2026 at sec.gov

Sources

The two latest 10-Ks on EDGAR, section by section. Each change links to the text at sec.gov.

Also

New risk factors: paragraphs with nothing like them last year, quoted in full.

Work with it

Excel workbook · CSV. Google Sheet that stays up to date: paste =IMPORTDATA("https://tickdelta.com/company/TFX/export.csv") into a cell.

Next:Related parties
Esc

Type a ticker such as AAPL, a name, an investor such as Buffett, or a topic such as tariffs. ↑ ↓ to move, Enter to open.